PHARPharming Group N.V.

Nasdaq pharming.com


$ 7.53 $ -0.03 (-0.33 %)    

Thursday, 12-Sep-2024 15:38:36 EDT
QQQ $ 474.86 $ 2.12 (0.45 %)
DIA $ 414.87 $ 2.97 (0.72 %)
SPY $ 561.82 $ 2.92 (0.52 %)
TLT $ 100.40 $ 0.27 (0.27 %)
GLD $ 238.66 $ 2.35 (0.99 %)
$ 7.5
-- x --
$ 8.01 x 100
-- - --
$ 6.65 - $ 16.71
2,683
na
503.3M
$ 0.59
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-pharming-maintains-37-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.

 pharming-group-expects-2024-total-revenue-of-280m-295m-14-to-20-growth-with-quarterly-fluctuations-expected

Outlook/Summary For 2024, the Company anticipates: Total revenues between US$280 million and US$295 million (14% to 20% gro...

 pharming-q2-eps-0002-down-from-0002-yoy-sales-7410m-up-from-5490m-yoy

Pharming (NASDAQ:PHAR) reported quarterly losses of $(0.00) per share. The company reported $74.10 million in sales this quarte...

 hc-wainwright--co-reiterates-buy-on-pharming-maintains-37-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.

 pharming-q1-2024-gaap-eps-002-misses-001-estimate-sales-55586m-miss-68425m-estimate

Pharming (NASDAQ:PHAR) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.01 by 2...

 reported-earlier-pharming-announces-completion-of-enrollment-in-pediatric-clinical-trial-of-leniolisib

Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the completion of patient enrollment ...

 hc-wainwright--co-reiterates-buy-on-pharming-maintains-37-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.

 earnings-scheduled-for-march-14-2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

 pharming-group-expects-2024-total-revenue-of-280m-295m

Outlook/Summary For 2024, the Company anticipates: Total revenues between US$280 million and US$295 million (14% to 20% gro...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION